Mono Pharmacare

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE0OIP01012
NSEID: MONOPHARMA
BSEID:

INR

15.75

0.55 (3.62%)

BSENSE

Dec 26

BSE+NSE Vol: 2000

{
  "main_header": {
    "sid": 10038990,
    "name": "Mono Pharmacare",
    "stock_name": "Mono Pharmacare",
    "full_name": "Mono Pharmacare Ltd",
    "name_url": "stocks-analysis/mono-pharmacare",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "15.75",
    "chg": 0.55,
    "chgp": "3.62%",
    "dir": 1,
    "prev_price": "15.20",
    "mcapval": "28.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "MONOPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0OIP01012",
    "curr_date": "Dec 26",
    "curr_time": "",
    "bse_nse_vol": 2000,
    "exc_status": "Active",
    "traded_date": "Dec 26, 2025",
    "traded_date_str": "2025 12 26",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mono-pharmacare-10038990-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Mono Pharmacare falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-mono-pharmacare-fallingrising-3757872",
        "imagepath": "",
        "date": "2025-12-13 01:24:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Persistent Downward Trend Against Market Benchmarks</strong></p>\n<p>Mono Pharmacare’s recent price action underscores a continuing downtrend that has persisted over multiple time horizons. Over the past week, the stock has declined by 6.07%, significantly underperforming the Sensex benchmark, which fell only 0.53% during the same period. This negative momentum has extended over the last month, with the stock losing 13.38%, while the Sensex managed a modest gain of 0.66%. The divergence is even more pronounced on a year-to-date basis, where Mono Pharmacare has plummeted 48.63%, contrasting sharply with the Sensex’s 10.16% appreciation. Over the trailing twelve months, the stock’s decline deepened further to 50.69%, whereas the Sensex recorded a healthy 6.10% gain.</p>\n<p>These figures highlig..."
      },
      {
        "title": "How has been the historical performance of Mono Pharmacare?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-mono-pharmacare-3736028",
        "imagepath": "",
        "date": "2025-11-28 22:44:31",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the fiscal years ending March 2024 and March 2025, Mono Pharmacare’s net sales increased significantly, reflecting a robust expansion in its core operations. The company’s total operating income rose from ₹122.34 crores in March 2024 to ₹168.34 crores in March 2025, indicating a strong top-line momentum. This growth was primarily driven by an increase in the purchase of finished goods, which rose in tandem with sales, suggesting an operational scaling aligned with demand.</p>\n<p>Despite the increase in expenditure, including employee costs and other expenses, the company managed to enhance its operating profit (PBDIT) from ₹6.33 crores in March 2024 to ₹7.63 crores in March 2025, excluding other income. Including other income, operating p..."
      },
      {
        "title": "Why is Mono Pharmacare falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-mono-pharmacare-fallingrising-3716598",
        "imagepath": "",
        "date": "2025-11-20 00:18:30",
        "description": "As of 19-Nov, Mono Pharmacare Ltd is experiencing a decline in its stock price, currently at Rs 19.70, which reflects a decrease of Rs 0.75 or 3.67%. The stock has underperformed significantly, with a 1-week return of -4.14% and a 1-month return of -6.19%. It is also trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, the stock is close to its 52-week low, being only 2.81% away from it. Despite a rise in investor participation, with delivery volume increasing by 19.05% against the 5-day average, the overall performance remains weak, as indicated by the stock's substantial year-to-date decline of 43.15%.\n\nIn the broader market context, the Sensex has shown resilience with a 1-week gain of +0.68% and a year-to-date increase of +10.18%, contrasting sharply with Mono Pharmacare's poor performance. This divergence highlights the stock's st..."
      },
      {
        "title": "How has been the historical performance of Mono Pharmacare?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-mono-pharmacare-3713255",
        "imagepath": "",
        "date": "2025-11-18 23:03:08",
        "description": "Answer:\nThe historical performance of Mono Pharmacare shows a positive trend in key financial metrics from March 2024 to March 2025.\n\nBreakdown:\nIn the fiscal year ending March 2025, Mono Pharmacare reported net sales of 168.34 Cr, an increase from 122.34 Cr in the previous year. Total operating income also rose to 168.34 Cr from 122.34 Cr, while total expenditure increased to 160.71 Cr from 116.01 Cr. The operating profit (PBDIT) grew to 8.61 Cr from 6.43 Cr, reflecting an operating profit margin of 4.53%, down from 5.17%. Profit before tax improved to 4.46 Cr from 3.23 Cr, leading to a profit after tax of 3.11 Cr, up from 2.46 Cr. The consolidated net profit increased to 3.09 Cr from 2.44 Cr, with earnings per share rising to 1.75 from 1.38. On the balance sheet, total assets grew to 110.01 Cr from 81.10 Cr, with total liabilities also increasing to 110.01 Cr from 81.10 Cr. Cash flow from operating activi..."
      },
      {
        "title": "Is Mono Pharmacare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-mono-pharmacare-overvalued-or-undervalued-3687871",
        "imagepath": "",
        "date": "2025-11-11 08:14:59",
        "description": "As of 10 November 2025, the valuation grade for Mono Pharmacare has moved from very expensive to expensive. The company is currently considered overvalued based on its financial ratios. Key ratios include a PE Ratio of 11.72, an EV to EBITDA of 11.68, and a PEG Ratio of 0.44, which indicates potential growth at a reasonable price compared to its earnings.\n\nWhen comparing Mono Pharmacare to its peers, Sun Pharma has a significantly higher PE Ratio of 35.15, while Cipla, which is rated attractive, has a PE Ratio of 22.45. This suggests that Mono Pharmacare's valuation is not justified when looking at the broader industry context, especially given its recent stock performance, which has underperformed the Sensex over the past year, with a decline of 43.84% compared to the Sensex's gain of 5.91%...."
      },
      {
        "title": "Is Mono Pharmacare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-mono-pharmacare-overvalued-or-undervalued-3678214",
        "imagepath": "",
        "date": "2025-11-07 08:14:02",
        "description": "As of 6 November 2025, the valuation grade for Mono Pharmacare has moved from expensive to very expensive. This indicates a significant concern regarding its current valuation, suggesting that the company is overvalued. Key ratios reveal a PE Ratio of 11.72, an EV to EBITDA of 11.68, and a PEG Ratio of 0.44, which, while seemingly reasonable in isolation, do not justify the very expensive classification when compared to peers.\n\nIn comparison, Sun Pharma has a PE Ratio of 35.02 and an EV to EBITDA of 10.54, while Cipla is rated attractive with a PE of 22.27 and an EV to EBITDA of 5.53. These comparisons highlight that Mono Pharmacare's valuation is not only higher than attractive peers but also does not align with its performance metrics, reinforcing the view that it is overvalued. Additionally, the company's stock has underperformed significantly year-to-date, with a return of -40.84% compared to the Sensex..."
      },
      {
        "title": "Why is Mono Pharmacare falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-mono-pharmacare-fallingrising-3624439",
        "imagepath": "",
        "date": "2025-10-16 00:03:23",
        "description": "As of 15-Oct, Mono Pharmacare Ltd's stock price is currently at Rs 21.00, reflecting a decrease of Rs 0.4 or 1.87%. The stock has underperformed significantly, with a 1-week return of -7.89% and a 1-month return of -14.11%. It is also trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Furthermore, the stock is close to its 52-week low, just 1.67% away from Rs 20.65. Despite a rise in investor participation, with delivery volume increasing by 33.33% against the 5-day average, there are no positive factors noted that could counterbalance the negative performance.\n\nBroader Market Context: In comparison to the benchmark Sensex, which has shown a positive return of +1.11% over the past week and +1.01% over the past month, Mono Pharmacare's performance is notably poor. The broader market has been relatively stable, with the Sensex up 7.10% year-to-date,..."
      }
    ],
    "total": 54,
    "sid": "10038990",
    "stock_news_url": "https://www.marketsmojo.com/news/mono-pharmacare-10038990"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Mono Pharmacare falling/rising?

2025-12-13 01:24:26

Persistent Downward Trend Against Market Benchmarks

Mono Pharmacare’s recent price action underscores a continuing downtrend that has persisted over multiple time horizons. Over the past week, the stock has declined by 6.07%, significantly underperforming the Sensex benchmark, which fell only 0.53% during the same period. This negative momentum has extended over the last month, with the stock losing 13.38%, while the Sensex managed a modest gain of 0.66%. The divergence is even more pronounced on a year-to-date basis, where Mono Pharmacare has plummeted 48.63%, contrasting sharply with the Sensex’s 10.16% appreciation. Over the trailing twelve months, the stock’s decline deepened further to 50.69%, whereas the Sensex recorded a healthy 6.10% gain.

These figures highlig...

How has been the historical performance of Mono Pharmacare?

2025-11-28 22:44:31

Revenue and Profitability Trends

Over the fiscal years ending March 2024 and March 2025, Mono Pharmacare’s net sales increased significantly, reflecting a robust expansion in its core operations. The company’s total operating income rose from ₹122.34 crores in March 2024 to ₹168.34 crores in March 2025, indicating a strong top-line momentum. This growth was primarily driven by an increase in the purchase of finished goods, which rose in tandem with sales, suggesting an operational scaling aligned with demand.

Despite the increase in expenditure, including employee costs and other expenses, the company managed to enhance its operating profit (PBDIT) from ₹6.33 crores in March 2024 to ₹7.63 crores in March 2025, excluding other income. Including other income, operating p...

Why is Mono Pharmacare falling/rising?

2025-11-20 00:18:30

As of 19-Nov, Mono Pharmacare Ltd is experiencing a decline in its stock price, currently at Rs 19.70, which reflects a decrease of Rs 0.75 or 3.67%. The stock has underperformed significantly, with a 1-week return of -4.14% and a 1-month return of -6.19%. It is also trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, the stock is close to its 52-week low, being only 2.81% away from it. Despite a rise in investor participation, with delivery volume increasing by 19.05% against the 5-day average, the overall performance remains weak, as indicated by the stock's substantial year-to-date decline of 43.15%. In the broader market context, the Sensex has shown resilience with a 1-week gain of +0.68% and a year-to-date increase of +10.18%, contrasting sharply with Mono Pharmacare's poor performance. This divergence highlights the stock's st...

How has been the historical performance of Mono Pharmacare?

2025-11-18 23:03:08

Answer: The historical performance of Mono Pharmacare shows a positive trend in key financial metrics from March 2024 to March 2025. Breakdown: In the fiscal year ending March 2025, Mono Pharmacare reported net sales of 168.34 Cr, an increase from 122.34 Cr in the previous year. Total operating income also rose to 168.34 Cr from 122.34 Cr, while total expenditure increased to 160.71 Cr from 116.01 Cr. The operating profit (PBDIT) grew to 8.61 Cr from 6.43 Cr, reflecting an operating profit margin of 4.53%, down from 5.17%. Profit before tax improved to 4.46 Cr from 3.23 Cr, leading to a profit after tax of 3.11 Cr, up from 2.46 Cr. The consolidated net profit increased to 3.09 Cr from 2.44 Cr, with earnings per share rising to 1.75 from 1.38. On the balance sheet, total assets grew to 110.01 Cr from 81.10 Cr, with total liabilities also increasing to 110.01 Cr from 81.10 Cr. Cash flow from operating activi...

Is Mono Pharmacare overvalued or undervalued?

2025-11-11 08:14:59

As of 10 November 2025, the valuation grade for Mono Pharmacare has moved from very expensive to expensive. The company is currently considered overvalued based on its financial ratios. Key ratios include a PE Ratio of 11.72, an EV to EBITDA of 11.68, and a PEG Ratio of 0.44, which indicates potential growth at a reasonable price compared to its earnings. When comparing Mono Pharmacare to its peers, Sun Pharma has a significantly higher PE Ratio of 35.15, while Cipla, which is rated attractive, has a PE Ratio of 22.45. This suggests that Mono Pharmacare's valuation is not justified when looking at the broader industry context, especially given its recent stock performance, which has underperformed the Sensex over the past year, with a decline of 43.84% compared to the Sensex's gain of 5.91%....

Is Mono Pharmacare overvalued or undervalued?

2025-11-07 08:14:02

As of 6 November 2025, the valuation grade for Mono Pharmacare has moved from expensive to very expensive. This indicates a significant concern regarding its current valuation, suggesting that the company is overvalued. Key ratios reveal a PE Ratio of 11.72, an EV to EBITDA of 11.68, and a PEG Ratio of 0.44, which, while seemingly reasonable in isolation, do not justify the very expensive classification when compared to peers. In comparison, Sun Pharma has a PE Ratio of 35.02 and an EV to EBITDA of 10.54, while Cipla is rated attractive with a PE of 22.27 and an EV to EBITDA of 5.53. These comparisons highlight that Mono Pharmacare's valuation is not only higher than attractive peers but also does not align with its performance metrics, reinforcing the view that it is overvalued. Additionally, the company's stock has underperformed significantly year-to-date, with a return of -40.84% compared to the Sensex...

Why is Mono Pharmacare falling/rising?

2025-10-16 00:03:23

As of 15-Oct, Mono Pharmacare Ltd's stock price is currently at Rs 21.00, reflecting a decrease of Rs 0.4 or 1.87%. The stock has underperformed significantly, with a 1-week return of -7.89% and a 1-month return of -14.11%. It is also trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Furthermore, the stock is close to its 52-week low, just 1.67% away from Rs 20.65. Despite a rise in investor participation, with delivery volume increasing by 33.33% against the 5-day average, there are no positive factors noted that could counterbalance the negative performance. Broader Market Context: In comparison to the benchmark Sensex, which has shown a positive return of +1.11% over the past week and +1.01% over the past month, Mono Pharmacare's performance is notably poor. The broader market has been relatively stable, with the Sensex up 7.10% year-to-date,...

View All News